Internet Archive Scholar

MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors

Pier Paolo Leoncini, Patrizia Vitullo, Sofia Reddel, Valeria Tocco, Valeria Paganelli, Francesca Stocchi, Elena Mariggiò, Michele Massa, Giovanni Nigita, Dario Veneziano, Paolo Fadda, Mario Scarpa (+5 others)
2022

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.6 MB)
https://web.archive.org/web/20221114063557/https://boris.unibe.ch/174446/1/or_48_6_8436_PDF.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

Novel therapeutic strategies are needed for paediatric patients affected by Acute Myeloid Leukaemia (AML), particularly for those at high-risk for relapse. MicroRNAs (miRs) have been extensively studied as biomarkers in cancer and haematological disorders, and their expression has been correlated to the presence of recurrent molecular abnormalities, expression of oncogenes, as well as to prognosis/clinical outcome. In the present study, expression signatures of different miRs related both to
more » ... sence of myeloid/lymphoid or mixed-lineage leukaemia 1 and Fms like tyrosine kinase 3 internal tandem duplications rearrangements and to the clinical outcome of paediatric patients with AML were identified. Notably, miR-221-3p and miR-222-3p resulted as a possible relapse-risk related miR. Thus, miR-221-3p and miR-222-3p expression modulation was investigated by using a Bromodomain‑containing protein 4 (BRD4) inhibitor (JQ1) and a natural compound that acts as histone acetyl transferase inhibitor (curcumin), alone or in association, in order to decrease acetylation of histone tails and potentiate the effect of BRD4 inhibition. JQ1 modulates miR-221-3p and miR-222-3p expression in AML with a synergic effect when associated with curcumin. Moreover, changes were observed in the expression of CDKN1B, a known target of miR-221-3p and miR-222-3p, increase in apoptosis and downregulation of miR-221-3p and miR-222-3p expression in CD34+ AML primary cells. Altogether, these findings suggested that several miRs expression signatures at diagnosis may be used for risk stratification and as relapse prediction biomarkers in paediatric AML outlining that epigenetic drugs, could represent a novel therapeutic strategy for high-risk paediatric patients with AML. For these epigenetic drugs, additional research for enhancing activity, bioavailability and safety is needed.
doi:10.48350/174446 fatcat:63nnydjyi5ggtpwnlpvuvgarqe
Open Access
Citation

Pier Paolo Leoncini, Patrizia Vitullo, Sofia Reddel, Valeria Tocco, Valeria Paganelli, Francesca Stocchi, Elena Mariggiò, Michele Massa, Giovanni Nigita, Dario Veneziano, Paolo Fadda, Mario Scarpa, Martina Pigazzi, Alice Bertaina, Rossella Rota, Daria Pagliara, Pietro Merli. "MicroRNA profiling of paediatric AML with FLT-ITD or MLL-rearrangements: Expression signatures and in vitro modulation of miR-221-3p and miR-222-3p with BRD4/HATs inhibitors." (2022)